Ocular Therapeutix Inc share price logo

Ocular Therapeutix Inc Share Price

NASDAQ: OCUL

Small Cap

$8.61

-0.15

(-1.71%)

as on

Ocular Therapeutix Inc Stock Performance

as on March 17, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $8.46
    $9.04
    downward going graph

    1.74%

    Downside

    4.99%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $5.80
    $16.44
    downward going graph

    32.64%

    Downside

    90.94%

    Upside

    downward going graph

Ocular Therapeutix Inc share price movements today

Previous Close
$8.76
Open
$8.84
Volume
3.1M
Day's Low - High
$8.46 - $9.04
52 Week Low - High
$5.80 - $16.44

Ocular Therapeutix Inc Historical Returns

1 Month Return
-1.35 %
3 Month Return
-39.12 %
1 Year Return
+ 13.47 %
3 Year Return
+ 68.79 %
5 Year Return
-54.47 %

Ocular Therapeutix Inc Stock Fundamentals & Key Indicators

Check Ocular Therapeutix Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.9B

EPS (TTM)

-1.3975

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-9.65

Industry PE ratio

-3.2826206896551726

PEG Ratio

0

EBITDA

-265.7M

Revenue (TTM)

52.0M

Profit Margin

0.00%

Return On Equity TTM

-54.85%

Ocular Therapeutix Inc Stock Valuation

Track how Ocular Therapeutix Inc P/E has moved over time to understand its valuation trends.

Ocular Therapeutix Inc in the last 5 years

  • Overview

  • Trends

Lowest (-86.29x)

December 31, 2021

Today (-9.65x)

March 16, 2026

Industry (-3.28x)

March 16, 2026

Highest (-2.53x)

December 31, 2023

LowHigh

Today’s Price to Earnings Ratio: -9.65x

Ocular Therapeutix Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Ocular Therapeutix Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Ocular Therapeutix Inc image
Ocular Therapeutix Inc
BUY$1.9B-54.47%-9.650.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$41.6B117.98%135.098.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$119.2B114.32%30.6832.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$32.8BNA1155.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$78.8B54.67%17.9931.41%

Stock Returns calculator for Ocular Therapeutix Inc Stock including INR - Dollar returns

The Ocular Therapeutix Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Ocular Therapeutix Inc investment value today

Current value as on today

₹1,18,028

Returns

₹18,028

(+18.03%)

Returns from Ocular Therapeutix Inc Stock

₹11,528 (+11.53%)

Dollar Returns*

₹6,499 (+6.5%)

Analyst Recommendation on Ocular Therapeutix Inc Stock

Based on 14 analysts

BUY

85.71%

Buy

14.29%

Hold

0.00%

Sell

Based on 14 analysts, 85.71% of analysts recommend a 'BUY' rating for Ocular Therapeutix Inc. Average target price of $26.17

Ocular Therapeutix Inc Share Price Target

Get share price movements and forecasts by analysts on Ocular Therapeutix Inc.

What analysts predicted

67.1%UPSIDE

Target Price

$26.17

Current Price

$8.61

Analyzed by

14 Analysts

Target

$26.17

Ocular Therapeutix Inc target price $26.17, a slight upside of 67.1% compared to current price of $8.61. According to 14 analysts rating.

Ocular Therapeutix Inc Stock’s Investor Sentiment and Interest

Search interest for Ocular Therapeutix Inc Stock has increased by 132% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:132% versus previous 30 day period

Ocular Therapeutix Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
15
14
14
16
15
17
10
13
14
13
Gross Profit
13
13
13
14
13
15
9
11
12
11
Operating Income
-19
-20
-31
-43
-45
-50
-63
-67
-68
-69
EBITDA
3
-24
-59
-39
-32
-44
-60
-63
-65
-60
Interest Expense
3
4
4
3
3
3
2
3
3
2
Depreciation
0
0
0
0
0
0
0
1
1
1
Income Before Tax
0
-29
-64
-43
-36
-48
-64
-67
-69
-64
Income Tax Expense
0
-7
0
-
-
-
-
-
-
-
Net Income
0
-29
-64
-43
-36
-48
-64
-67
-69
-64
Net Profit Margin
-3.42%
-197.42%
-438.93%
-266.27%
-236.58%
-283.27%
-598.74%
-503.86%
-477.30%
-487.95%

Ocular Therapeutix Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
1
1
4
17
43
51
58
63
51
Gross Profit
1
1
1
1
15
39
46
53
58
45
Operating Income
-43
-61
-59
-85
-62
-78
-78
-82
-171
-270
EBITDA
-42
-59
-55
-77
-146
2
-61
-66
-176
-249
Interest Expense
1
1
1
6
6
6
7
11
13
11
Depreciation
-
1
2
2
2
2
2
2
3
4
Income Before Tax
-44
-63
-59
-86
-155
-6
-71
-80
-193
-265
Income Tax Expense
0
0
-2
3
3
4
-7
2
-
-
Net Income
-44
-63
-57
-86
-155
-6
-71
-80
-193
-265
Net Profit Margin
-2369.00%
-3296.20%
-2899.10%
-2043.34%
-894.31%
-15.06%
-137.95%
-138.14%
-303.67%
-513.17%

Ocular Therapeutix Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-29
-64
-43
-36
-48
-64
-67
-69
-64
Operating Cash Flow
-22
-33
-24
-36
-39
-44
-55
-50
-54
Investing Cash Flow
0
0
0
0
0
-1
-1
-5
-2
Financing Cash Flow
108
321
2
4
4
4
97
10
449
Change in Cash
85
287
-23
-32
-35
-42
41
-46
392

Ocular Therapeutix Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-63
-59
-86
-155
-6
-71
-80
-193
-265
Operating Cash Flow
-50
-49
-77
-53
-65
-59
-70
-134
-204
Investing Cash Flow
27
-1
-2
0
-1
-3
-6
-1
-11
Financing Cash Flow
32
68
75
228
2
1
169
332
561
Change in Cash
8
17
-4
173
-63
-61
93
196
344

Global Institutional Holdings in Ocular Therapeutix Inc

Funds
Holdings
Paradigm Biocapital Advisors LP
1.35%
VR Adviser, LLC
3.36%
SUMMER ROAD LLC
5.78%
Millennium Management LLC
1.47%
venBio Select Advisor LLC
4.95%
See all

Ocular Therapeutix Inc News & Key Events

  • img

    Today's Timeline - 02 October

    Thu, 10:16 AM

    -

    Ocular Therapeutix shares drop 6.7% after announcing $475 million share sale to fund clinical trials and infrastructure.

    Thu, 03:22 PM

    -

    Analyst reiterates Buy rating for Ocular Therapeutix, citing promising clinical trials and strategic advancements.

Insights on Ocular Therapeutix Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, OCUL has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -69.41M → -64.65M (in $), with an average increase of 7.4% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 29.6% return, outperforming this stock by 16.1%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, OCUL stock has moved down by -11.9%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 14.54M → 13.25M (in $), with an average decrease of 8.9% per quarter

About Ocular Therapeutix Inc

ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
OrganisationOcular Therapeutix Inc
Headquarters15 Crosby Drive, Bedford, MA, United States, 01730
IndustryHealth Technology
CEODr. Pravin U. Dugel M.D.
E-voting on sharesClick here to vote

Key Management of Ocular Therapeutix Inc

Name

Title

Mr. William S. Slattery Jr.

Vice President of Investor Relations

Mr. William H. Ransone II

Vice President of Global Sales & Marketing

Mr. Barry Rubenstein M.S.

Chief Human Resources Officer

Mr. Donald Notman Jr.

CFO, COO & Principal Accounting Officer (Leave of Absence)

Dr. Pravin U. Dugel M.D.

Executive Chairman, President & CEO

Dr. Peter K. Kaiser M.D.

Chief Development Officer

Mr. Jason Robins

Senior VP of Finance, Interim CFO & Principal Accounting Officer

Dr. Peter K. Jarrett Ph.D.

Chief Technical Officer

Dr. Jeffrey S. Heier M.D.

Chief Scientific Officer

Mr. Todd D.C. Anderman J.D.

Chief Legal Officer & Corporate Secretary

FAQs

What is Ocular Therapeutix Inc share price today?

Ocular Therapeutix Inc share price today is $8.61 as on at the close of the market. Ocular Therapeutix Inc share today touched a day high of $9.04 and a low of $8.46.

What is the 52 week high and 52 week low for Ocular Therapeutix Inc share?

Ocular Therapeutix Inc share touched a 52 week high of $16.44 on and a 52 week low of $5.8 on . Ocular Therapeutix Inc stock price today i.e. is closed at $8.61,which is 47.63% down from its 52 week high and 48.45% up from its 52 week low.

What is Ocular Therapeutix Inc's market capitalisation today?

Ocular Therapeutix Inc market capitalisation is $0.00T as on .

How to invest in Ocular Therapeutix Inc Stock (OCUL) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Ocular Therapeutix Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Ocular Therapeutix Inc Shares that will get you 0.1742 shares as per Ocular Therapeutix Inc share price of $8.61 per share as on March 17, 2026 at 1:29 am IST.

What is the minimum amount required to buy Ocular Therapeutix Inc Stock (OCUL) from India?

Indian investors can start investing in Ocular Therapeutix Inc (OCUL) shares with as little as ₹92.335 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹923.35 in Ocular Therapeutix Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Ocular Therapeutix Inc share’s latest price of $8.61 as on March 17, 2026 at 1:29 am IST, you will get 1.1614 shares of Ocular Therapeutix Inc. Learn more about fractional shares .

What are the returns that Ocular Therapeutix Inc has given to Indian investors in the last 5 years?

Ocular Therapeutix Inc stock has given -54.47% share price returns and 27.61% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?